Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders
Federica Moraca, Simona Marzano, Francesco D’Amico, Antonio Lupia, S. Di Fonzo, Eleonora Vertecchi, Erica Salvati, Anna Di Porzio, Bruno Catalanotti, Antonio Randazzo, Bruno Pagano, Jussara Amato
Abstract
Ligand-based virtual screening and biophysical techniques have been used to identify FDA approved drugs able to bind and stabilize SARS-CoV-2 G-quadruplex-forming RNA and to provide the molecular basis of the interactions.
Topics & Concepts
Drug repositioningRepurposingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)DrugChemistryLigand (biochemistry)2019-20 coronavirus outbreakRNAVirologyComputational biologyPharmacologyCombinatorial chemistryBiologyMedicineBiochemistryReceptorEcologyPathologyGeneDiseaseInfectious disease (medical specialty)OutbreakDNA and Nucleic Acid ChemistryAdvanced biosensing and bioanalysis techniquesRNA Interference and Gene Delivery